Resistance to estrogen-deprivation therapy is common in ER+ breast cancer tissue. To better understand this evolution to resistance, genomic characterization of multiple primary tumors is imperative for comprehensive results and identifying therapeutic targets (http://www.nature.com/ncomms/2016/160809/ncomms12498/full/ncomms12498.html#acknowledgments). For researchers, attaining samples that have been confirmed for diagnosis and receptor expression supports the inherent need for accuracy in tissue characterization.
Asterand Bioscience has a variety of FFPE and flash frozen tissue samples on demand through our biobank. These specimens cover a broad spectrum of anatomic sites, diseases and are approved by the IRB. Additionally, our Board Certified Clinical Pathologists confirm tissue, diagnosis and specimen quality to ensure our clients are provided with a superior product.
For more information on how we can help you with your tissue procurement needs, please feel free to contact us.